2.1.2. Inflammatory Markers Study 1

There was a significant reduction in CRP (−27%) in the 4 g dose in the overweight participants (*p =* 0.03) and a trend towards a reduction in CRP (−27%) in the 2 g dose in the obese participants (*p =* 0.06), as determined by a Kruskal–Wallis test (Figure 2). The obese group started at a considerably higher inflammation status than the overweight group.

**Figure 2.** The mean change in CRP after 6 weeks of each of the three treatments for overweight *n* = 30 (Placebo = 11, 2 g = 10, and 4 g = 9) and obese participants *n* = 30 (Placebo = 9, 2 g = 9, and 4 g = 12), separately. Standard error bars shown. \* Significant at *p* < 0.05.
